Halozyme Therapeutics (NASDAQ:HALO) Rating Increased to Strong-Buy at Zacks Research

Key Points

• Halozyme Therapeutics has been upgraded from a "hold" rating to a "strong-buy" by Zacks Research, which has also projected Q2 2026 earnings at $1.24 EPS.
• Wells Fargo raised its price target for the company to $65.00, while JMP Securities increased it to $91.00, indicating positive sentiment among analysts despite some conflicting ratings.
• Halozyme reported $1.54 EPS for its last quarter, exceeding expectations and reflecting a 40.8% year-over-year revenue increase, with forecasted FY 2025 guidance of 6.000-6.400 EPS.

Zacks Research upgraded shares of Halozyme Therapeutics (NASDAQ:HALO - Free Report) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Halozyme Therapeutics' Q2 2026 earnings at $1.24 EPS.

Other equities research analysts have also issued research reports about the stock. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a report on Tuesday, May 13th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 6th. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $67.11.

Halozyme Therapeutics Stock Performance

HALO traded up $0.92 during trading on Tuesday, hitting $75.85. The company's stock had a trading volume of 1,805,506 shares, compared to its average volume of 1,974,138. The business's 50 day simple moving average is $62.80 and its 200-day simple moving average is $59.84. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The firm has a market cap of $8.87 billion, a PE ratio of 17.36, a P/E/G ratio of 0.41 and a beta of 1.19. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $76.28.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares in the company, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,000 shares of company stock worth $6,316,120. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of HALO. DLD Asset Management LP acquired a new position in Halozyme Therapeutics during the second quarter valued at approximately $650,250,000. Arrowstreet Capital Limited Partnership boosted its stake in Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company's stock valued at $132,192,000 after purchasing an additional 1,425,674 shares during the period. Qube Research & Technologies Ltd acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $51,295,000. Los Angeles Capital Management LLC raised its holdings in shares of Halozyme Therapeutics by 951.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company's stock worth $50,650,000 after buying an additional 881,094 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $45,027,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.